美国iBio  
iBio 公司是一家生物制药公司，该公司将其专利技术 iBioLaunch™平台商业化用于包括疫苗和治疗性蛋白在内的生物制剂的生产。iBioLaunch 平台使用绿色植物瞬时基因表达技术，以获得较高的蛋白生产效率。其优势是降低资本和工艺成本，其技术非常适合于注重速度、可伸缩性和过负荷能力的传染病应用。 iBio 公司的战略是将其技术用于其自己的候选产品的开发和制造，同时与企业客户和政府客户合作，减少他们在产品开发过程中的成本并满足低成本高质量生物制剂制造系统的需要。iBio 公司拥有在 Fraunhofer 美国分子生物科技中心研发的技术，同时不断支持技术的研发和完善，以广泛应用于人类医疗保健。

iBio, Inc. (IBIO:AMEX), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBioLaunch™ platform. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals. This unique plant-based platform offers a number of significant advantages over other systems:

• Ability to synthesize complex proteins at which other systems have failed

• Simplicity, scalability and flexibility

• Reduced capital investment

• Lower operating costs

• Surge capacity

• Rapid production times – gene sequence to factory-scale protein harvest

• Eliminates the need of bioreactors

• Low risk of contamination by animal pathogens

iBio has a strong IP/technology portfolio and has been well established by more than nine years of applications development and $100 million in funding. Our current pipeline includes:

• Monoclonal antibodies

• Interferons & cytokines

• Enzymes for replacement therapy

• Plasma-derived proteins

• Growth factors

• Protease inhibitors

• Clotting factors

• Vaccines